{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:14:34Z","timestamp":1790525674279,"version":"4.1.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1038\/s41581-020-0260-2","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T11:03:15Z","timestamp":1583492595000},"page":"289-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Targeting angiogenesis and lymphangiogenesis in kidney disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4767-5892","authenticated-orcid":false,"given":"Katsuyuki","family":"Tanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-7553","authenticated-orcid":false,"given":"Yasufumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"260_CR1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster, A. C., Nagler, E. V., Morton, R. L. & Masson, P. Chronic kidney disease. Lancet 389, 1238\u20131252 (2017).","journal-title":"Lancet"},{"key":"260_CR2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00467-013-2430-y","volume":"29","author":"Y Kida","year":"2014","unstructured":"Kida, Y., Tchao, B. N. & Yamaguchi, I. Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease. Pediatr. Nephrol. 29, 333\u2013342 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"260_CR3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.kint.2016.07.038","volume":"91","author":"J Babickova","year":"2017","unstructured":"Babickova, J. et al. Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries. Kidney Int. 91, 70\u201385 (2017).","journal-title":"Kidney Int."},{"key":"260_CR4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrneph.2013.35","volume":"9","author":"T Tanaka","year":"2013","unstructured":"Tanaka, T. & Nangaku, M. Angiogenesis and hypoxia in the kidney. Nat. Rev. Nephrol. 9, 211\u2013222 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"260_CR5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fonc.2018.00248","volume":"8","author":"I Zuazo-Gaztelu","year":"2018","unstructured":"Zuazo-Gaztelu, I. & Casanovas, O. Unraveling the role of angiogenesis in cancer ecosystems. Front. Oncol. 8, 248 (2018).","journal-title":"Front. Oncol."},{"key":"260_CR6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17, 457\u2013474 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"260_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03351-7","author":"R Lugano","year":"2019","unstructured":"Lugano, R., Ramachandran, M. & Dimberg, A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. https:\/\/doi.org\/10.1007\/s00018-019-03351-7 (2019).","journal-title":"Cell. Mol. Life Sci."},{"key":"260_CR8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte, R. S., Chen, D. S. & Ferrara, N. VEGF in signaling and disease: beyond discovery and development. Cell 176, 1248\u20131264 (2019).","journal-title":"Cell"},{"key":"260_CR9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina, V. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707\u2013716 (2003).","journal-title":"J. Clin. Invest."},{"key":"260_CR10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129\u20131136 (2008).","journal-title":"N. Engl. J. Med."},{"key":"260_CR11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fphys.2019.00251","volume":"10","author":"PS Russell","year":"2019","unstructured":"Russell, P. S., Hong, J., Windsor, J. A., Itkin, M. & Phillips, A. R. J. Renal lymphatics: anatomy, physiology, and clinical implications. Front. Physiol. 10, 251 (2019).","journal-title":"Front. Physiol."},{"key":"260_CR12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fbioe.2018.00007","volume":"6","author":"K Rauniyar","year":"2018","unstructured":"Rauniyar, K., Jha, S. K. & Jeltsch, M. Biology of vascular endothelial growth factor C in the morphogenesis of lymphatic vessels. Front. Bioeng. Biotechnol. 6, 7 (2018).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"260_CR13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/bjs.18004217204","volume":"42","author":"FT Graves","year":"1954","unstructured":"Graves, F. T. The anatomy of the intrarenal arteries and its application to segmental resection of the kidney. Br. J. Surg. 42, 132\u2013139 (1954).","journal-title":"Br. J. Surg."},{"key":"260_CR14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bju.13788","volume":"120","author":"V Macchi","year":"2017","unstructured":"Macchi, V. et al. Anatomical study of renal arterial vasculature and its potential impact on partial nephrectomy. BJU Int. 120, 83\u201391 (2017).","journal-title":"BJU Int."},{"key":"260_CR15","first-page":"231","volume":"24","author":"H Dimke","year":"2015","unstructured":"Dimke, H., Maezawa, Y. & Quaggin, S. E. Crosstalk in glomerular injury and repair. Curr. Opin. Nephrol. Hypertens. 24, 231\u2013238 (2015).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"260_CR16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/HYPERTENSIONAHA.116.08319","volume":"69","author":"AR Chade","year":"2017","unstructured":"Chade, A. R. Small vessels, big role: renal microcirculation and progression of renal injury. Hypertension 69, 551\u2013563 (2017).","journal-title":"Hypertension"},{"key":"260_CR17","doi-asserted-by":"crossref","first-page":"5724069","DOI":"10.1155\/2017\/5724069","volume":"2017","author":"K Tanabe","year":"2017","unstructured":"Tanabe, K., Maeshima, Y., Sato, Y. & Wada, J. Antiangiogenic therapy for diabetic nephropathy. Biomed Res. Int. 2017, 5724069 (2017).","journal-title":"Biomed Res. Int."},{"key":"260_CR18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrm.2016.87","volume":"17","author":"M Simons","year":"2016","unstructured":"Simons, M., Gordon, E. & Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 17, 611\u2013625 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"260_CR19","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3390\/ijms19071859","volume":"19","author":"K Tanabe","year":"2018","unstructured":"Tanabe, K., Sato, Y. & Wada, J. Endogenous antiangiogenic factors in chronic kidney disease: potential biomarkers of progression. Int. J. Mol. Sci. 19, 1859 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"260_CR20","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/ijms19041264","volume":"19","author":"CJ Peach","year":"2018","unstructured":"Peach, C. J. et al. Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. Int. J. Mol. Sci. 19, 1264 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"260_CR21","doi-asserted-by":"crossref","first-page":"29120","DOI":"10.1074\/jbc.R115.687327","volume":"290","author":"HF Guo","year":"2015","unstructured":"Guo, H. F. & Vander Kooi, C. W. Neuropilin functions as an essential cell surface receptor. J. Biol. Chem. 290, 29120\u201329126 (2015).","journal-title":"J. Biol. Chem."},{"key":"260_CR22","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/ki.1992.441","volume":"42","author":"LF Brown","year":"1992","unstructured":"Brown, L. F. et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int. 42, 1457\u20131461 (1992).","journal-title":"Kidney Int."},{"key":"260_CR23","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1046\/j.1523-1755.2000.00103.x","volume":"57","author":"J Kanellis","year":"2000","unstructured":"Kanellis, J., Mudge, S. J., Fraser, S., Katerelos, M. & Power, D. A. Redistribution of cytoplasmic VEGF to the basolateral aspect of renal tubular cells in ischemia-reperfusion injury. Kidney Int. 57, 2445\u20132456 (2000).","journal-title":"Kidney Int."},{"key":"260_CR24","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu, S., Kim, C., Baer, L. & Zhu, X. Bevacizumab increases risk for severe proteinuria in cancer patients. J. Am. Soc. Nephrol. 21, 1381\u20131389 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR25","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi, J. J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med. 375, 1457\u20131467 (2016).","journal-title":"N. Engl. J. Med."},{"key":"260_CR26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person, F. et al. Bevacizumab-associated glomerular microangiopathy. Mod. Pathol. 32, 684\u2013700 (2019).","journal-title":"Mod. Pathol."},{"key":"260_CR27","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","volume":"80","author":"P Kandula","year":"2011","unstructured":"Kandula, P. & Agarwal, R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 80, 1271\u20131277 (2011).","journal-title":"Kidney Int."},{"key":"260_CR28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine, H. et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine 93, 333\u2013339 (2014).","journal-title":"Medicine"},{"key":"260_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada, C. C., Maldonado, A. & Mallipattu, S. K. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J. Am. Soc. Nephrol. 30, 187\u2013200 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR30","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.2014010060","volume":"26","author":"H Dimke","year":"2015","unstructured":"Dimke, H. et al. Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney. J. Am. Soc. Nephrol. 26, 1027\u20131038 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR31","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2353\/ajpath.2009.080792","volume":"175","author":"S Hakroush","year":"2009","unstructured":"Hakroush, S. et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am. J. Pathol. 175, 1883\u20131895 (2009).","journal-title":"Am. J. Pathol."},{"key":"260_CR32","doi-asserted-by":"crossref","first-page":"ra42","DOI":"10.1126\/scisignal.aad3812","volume":"9","author":"L Roth","year":"2016","unstructured":"Roth, L. et al. Neuropilin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation. Sci. Signal. 9, ra42 (2016).","journal-title":"Sci. Signal."},{"key":"260_CR33","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2337\/db14-0719","volume":"64","author":"PK Aggarwal","year":"2015","unstructured":"Aggarwal, P. K. et al. Semaphorin3a promotes advanced diabetic nephropathy. Diabetes 64, 1743\u20131759 (2015).","journal-title":"Diabetes"},{"key":"260_CR34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature08995","volume":"465","author":"S Sawamiphak","year":"2010","unstructured":"Sawamiphak, S. et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465, 487\u2013491 (2010).","journal-title":"Nature"},{"key":"260_CR35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1681\/ASN.2012080871","volume":"24","author":"Y Kida","year":"2013","unstructured":"Kida, Y., Ieronimakis, N., Schrimpf, C., Reyes, M. & Duffield, J. S. EphrinB2 reverse signaling protects against capillary rarefaction and fibrosis after kidney injury. J. Am. Soc. Nephrol. 24, 559\u2013572 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrc3484","volume":"13","author":"SP Becerra","year":"2013","unstructured":"Becerra, S. P. & Notario, V. The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat. Rev. Cancer 13, 258\u2013271 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"260_CR37","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/ndt\/gfn659","volume":"24","author":"T Fujimura","year":"2009","unstructured":"Fujimura, T. et al. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol. Dial. Transplant. 24, 1397\u20131406 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"260_CR38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen, P., Eklund, L. & Alitalo, K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat. Rev. Drug. Discov. 16, 635\u2013661 (2017).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"260_CR39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1681\/ASN.2008020243","volume":"20","author":"AS Woolf","year":"2009","unstructured":"Woolf, A. S., Gnudi, L. & Long, D. A. Roles of angiopoietins in kidney development and disease. J. Am. Soc. Nephrol. 20, 239\u2013244 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR40","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1681\/ASN.2017010069","volume":"28","author":"SM Parikh","year":"2017","unstructured":"Parikh, S. M. The angiopoietin-Tie2 signaling axis in systemic inflammation. J. Am. Soc. Nephrol. 28, 1973\u20131982 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR41","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1083\/jcb.200811159","volume":"185","author":"M Winderlich","year":"2009","unstructured":"Winderlich, M. et al. VE-PTP controls blood vessel development by balancing Tie-2 activity. J. Cell Biol. 185, 657\u2013671 (2009).","journal-title":"J. Cell Biol."},{"key":"260_CR42","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1073\/pnas.1714446115","volume":"115","author":"T Souma","year":"2018","unstructured":"Souma, T. et al. Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP. Proc. Natl Acad. Sci. USA 115, 1298\u20131303 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"260_CR43","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaci.2017.05.020","volume":"141","author":"V Bafunno","year":"2018","unstructured":"Bafunno, V. et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J. Allergy Clin. Immunol. 141, 1009\u20131017 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"260_CR44","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/cea.13349","volume":"49","author":"M d\u2019Apolito","year":"2019","unstructured":"d\u2019Apolito, M. et al. Angiopoietin-1 haploinsufficiency affects the endothelial barrier and causes hereditary angioedema. Clin. Exp. Allergy 49, 626\u2013635 (2019).","journal-title":"Clin. Exp. Allergy"},{"key":"260_CR45","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1681\/ASN.V1081722","volume":"10","author":"HT Yuan","year":"1999","unstructured":"Yuan, H. T., Suri, C., Yancopoulos, G. D. & Woolf, A. S. Expression of angiopoietin-1, angiopoietin-2, and the Tie-2 receptor tyrosine kinase during mouse kidney maturation. J. Am. Soc. Nephrol. 10, 1722\u20131736 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR46","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1172\/JCI46322","volume":"121","author":"M Jeansson","year":"2011","unstructured":"Jeansson, M. et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J. Clin. Invest. 121, 2278\u20132289 (2011).","journal-title":"J. Clin. Invest."},{"key":"260_CR47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189433","volume":"13","author":"K Loganathan","year":"2018","unstructured":"Loganathan, K. et al. Angiopoietin-1 deficiency increases renal capillary rarefaction and tubulointerstitial fibrosis in mice. PLoS One 13, e0189433 (2018).","journal-title":"PLoS One"},{"key":"260_CR48","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1681\/ASN.2017090962","volume":"29","author":"Y Kenig-Kozlovsky","year":"2018","unstructured":"Kenig-Kozlovsky, Y. et al. Ascending vasa recta are angiopoietin\/Tie2-dependent lymphatic-like vessels. J. Am. Soc. Nephrol. 29, 1097\u20131107 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR49","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1681\/ASN.2006101093","volume":"18","author":"B Davis","year":"2007","unstructured":"Davis, B. et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J. Am. Soc. Nephrol. 18, 2320\u20132329 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR50","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.30230","volume":"69","author":"AS Allegretti","year":"2019","unstructured":"Allegretti, A. S. et al. Serum angiopoietin-2 predicts mortality and kidney outcomes in decompensated cirrhosis. Hepatology 69, 729\u2013741 (2019).","journal-title":"Hepatology"},{"key":"260_CR51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/resp.13464","volume":"24","author":"CB Araujo","year":"2019","unstructured":"Araujo, C. B. et al. Angiopoietin-2 as a predictor of acute kidney injury in critically ill patients and association with ARDS. Respirology 24, 345\u2013351 (2019).","journal-title":"Respirology"},{"key":"260_CR52","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bph.12344","volume":"170","author":"AE El-Kenawi","year":"2013","unstructured":"El-Kenawi, A. E. & El-Remessy, A. B. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br. J. Pharmacol. 170, 712\u2013729 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"260_CR53","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.bbagen.2015.09.007","volume":"1850","author":"A Walia","year":"2015","unstructured":"Walia, A. et al. Endostatin\u2019s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim. Biophys. Acta 1850, 2422\u20132438 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"260_CR54","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1096\/fj.04-2134rev","volume":"19","author":"AG Marneros","year":"2005","unstructured":"Marneros, A. G. & Olsen, B. R. Physiological role of collagen XVIII and endostatin. FASEB J. 19, 716\u2013728 (2005).","journal-title":"FASEB J."},{"key":"260_CR55","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/hmg\/ddh213","volume":"13","author":"A Utriainen","year":"2004","unstructured":"Utriainen, A. et al. Structurally altered basement membranes and hydrocephalus in a type XVIII collagen deficient mouse line. Hum. Mol. Genet. 13, 2089\u20132099 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"260_CR56","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1681\/ASN.2009050492","volume":"21","author":"Y Hamano","year":"2010","unstructured":"Hamano, Y. et al. Lack of collagen XVIII\/endostatin exacerbates immune-mediated glomerulonephritis. J. Am. Soc. Nephrol. 21, 1445\u20131455 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR57","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.kint.2018.09.019","volume":"95","author":"K Chauhan","year":"2019","unstructured":"Chauhan, K. et al. Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes. Kidney Int. 95, 439\u2013446 (2019).","journal-title":"Kidney Int."},{"key":"260_CR58","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1172\/JCI200421152","volume":"114","author":"K Watanabe","year":"2004","unstructured":"Watanabe, K. et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J. Clin. Invest. 114, 898\u2013907 (2004).","journal-title":"J. Clin. Invest."},{"key":"260_CR59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046459","volume":"7","author":"H Miyashita","year":"2012","unstructured":"Miyashita, H. et al. Angiogenesis inhibitor vasohibin-1 enhances stress resistance of endothelial cells via induction of SOD2 and SIRT1. PLoS One 7, e46459 (2012).","journal-title":"PLoS One"},{"key":"260_CR60","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1182\/blood-2008-07-170316","volume":"113","author":"H Kimura","year":"2009","unstructured":"Kimura, H. et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood 113, 4810\u20134818 (2009).","journal-title":"Blood"},{"key":"260_CR61","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2353\/ajpath.2009.080788","volume":"175","author":"T Hosaka","year":"2009","unstructured":"Hosaka, T. et al. Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am. J. Pathol. 175, 430\u2013439 (2009).","journal-title":"Am. J. Pathol."},{"key":"260_CR62","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3892\/ol.2013.1119","volume":"5","author":"T Koyanagi","year":"2013","unstructured":"Koyanagi, T. et al. Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells. Oncol. Lett. 5, 1058\u20131062 (2013).","journal-title":"Oncol. Lett."},{"key":"260_CR63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.scr.2010.03.005","volume":"5","author":"R Olmer","year":"2010","unstructured":"Olmer, R. et al. Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defined medium. Stem Cell Res. 5, 51\u201364 (2010).","journal-title":"Stem Cell Res."},{"key":"260_CR64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/cas.13157","volume":"108","author":"R Norita","year":"2017","unstructured":"Norita, R. et al. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-beta signaling. Cancer Sci. 108, 419\u2013426 (2017).","journal-title":"Cancer Sci."},{"key":"260_CR65","doi-asserted-by":"crossref","first-page":"9851380","DOI":"10.1155\/2017\/9851380","volume":"2017","author":"E Takeda","year":"2017","unstructured":"Takeda, E., Suzuki, Y., Yamada, T., Katagiri, H. & Sato, Y. Knockout of vasohibin-1 gene in mice results in healthy longevity with reduced expression of insulin receptor, insulin receptor substrate 1, and insulin receptor substrate 2 in their white adipose tissue. J. Aging Res. 2017, 9851380 (2017).","journal-title":"J. Aging Res."},{"key":"260_CR66","doi-asserted-by":"crossref","first-page":"F264","DOI":"10.1152\/ajprenal.00045.2019","volume":"317","author":"S Tanimura","year":"2019","unstructured":"Tanimura, S. et al. Renal tubular injury exacerbated by vasohibin-1 deficiency in a murine cisplatin-induced acute kidney injury model. Am. J. Physiol. Renal Physiol. 317, F264\u2013F274 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"260_CR67","volume":"13","author":"K Masuda","year":"2018","unstructured":"Masuda, K. et al. Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model. PLoS One 13, e0195779 (2018).","journal-title":"PLoS One"},{"key":"260_CR68","volume":"9","author":"N Hinamoto","year":"2014","unstructured":"Hinamoto, N. et al. Urinary and plasma levels of vasohibin-1 can predict renal functional deterioration in patients with renal disorders. PLoS One 9, e96932 (2014).","journal-title":"PLoS One"},{"key":"260_CR69","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jdiacomp.2019.04.008","volume":"33","author":"H Ren","year":"2019","unstructured":"Ren, H. et al. Expression levels of serum vasohibin-1 and other biomarkers in type 2 diabetes mellitus patients with different urinary albumin to creatinine ratios. J. Diabetes Complicat. 33, 477\u2013484 (2019).","journal-title":"J. Diabetes Complicat."},{"key":"260_CR70","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-beta: the master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325\u2013338 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"260_CR71","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.tcb.2010.06.006","volume":"20","author":"E Pardali","year":"2010","unstructured":"Pardali, E., Goumans, M. J. & ten Dijke, P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 20, 556\u2013567 (2010).","journal-title":"Trends Cell Biol."},{"key":"260_CR72","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1182\/blood-2011-01-330142","volume":"117","author":"SI Cunha","year":"2011","unstructured":"Cunha, S. I. & Pietras, K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 117, 6999\u20137006 (2011).","journal-title":"Blood"},{"key":"260_CR73","doi-asserted-by":"crossref","first-page":"H959","DOI":"10.1152\/ajpheart.01251.2009","volume":"299","author":"JM Lopez-Novoa","year":"2010","unstructured":"Lopez-Novoa, J. M. & Bernabeu, C. The physiological role of endoglin in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 299, H959\u2013H974 (2010).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"260_CR74","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/14728222.2017.1365839","volume":"21","author":"L Ruiz-Llorente","year":"2017","unstructured":"Ruiz-Llorente, L. et al. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. Expert. Opin. Ther. Targets 21, 933\u2013947 (2017).","journal-title":"Expert. Opin. Ther. Targets"},{"key":"260_CR75","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature12345","volume":"499","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 499, 306\u2013311 (2013).","journal-title":"Nature"},{"key":"260_CR76","doi-asserted-by":"crossref","first-page":"2817045","DOI":"10.1155\/2018\/2817045","volume":"2018","author":"S Haku","year":"2018","unstructured":"Haku, S. et al. Early enhanced leucine-rich alpha-2-glycoprotein-1 expression in glomerular endothelial cells of type 2 diabetic nephropathy model mice. Biomed Res. Int. 2018, 2817045 (2018).","journal-title":"Biomed Res. Int."},{"key":"260_CR77","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1681\/ASN.2018060599","volume":"30","author":"Q Hong","year":"2019","unstructured":"Hong, Q. et al. LRG1 promotes diabetic kidney disease progression by enhancing TGF-beta-induced angiogenesis. J. Am. Soc. Nephrol. 30, 546\u2013562 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR78","doi-asserted-by":"crossref","first-page":"dev.151019","DOI":"10.1242\/dev.151019","volume":"145","author":"S Karaman","year":"2018","unstructured":"Karaman, S., Leppanen, V. M. & Alitalo, K. Vascular endothelial growth factor signaling in development and disease. Development 145, dev.151019 (2018).","journal-title":"Development"},{"key":"260_CR79","volume":"8","author":"SK Jha","year":"2019","unstructured":"Jha, S. K. et al. KLK3\/PSA and cathepsin D activate VEGF-C and VEGF-D. eLife 8, e44478 (2019).","journal-title":"eLife"},{"key":"260_CR80","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1002\/dvdy.21208","volume":"236","author":"MT Dellinger","year":"2007","unstructured":"Dellinger, M. T., Hunter, R. J., Bernas, M. J., Witte, M. H. & Erickson, R. P. Chy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasia. Dev. Dyn. 236, 2346\u20132355 (2007).","journal-title":"Dev. Dyn."},{"key":"260_CR81","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/jmedgenet-2013-102020","volume":"51","author":"E Balboa-Beltran","year":"2014","unstructured":"Balboa-Beltran, E. et al. A novel stop mutation in the vascular endothelial growth factor-C gene (VEGFC) results in Milroy-like disease. J. Med. Genet. 51, 475\u2013478 (2014).","journal-title":"J. Med. Genet."},{"key":"260_CR82","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.15252\/emmm.201505731","volume":"7","author":"H Nurmi","year":"2015","unstructured":"Nurmi, H. et al. VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption. EMBO Mol. Med. 7, 1418\u20131425 (2015).","journal-title":"EMBO Mol. Med."},{"key":"260_CR83","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1128\/MCB.25.6.2441-2449.2005","volume":"25","author":"ME Baldwin","year":"2005","unstructured":"Baldwin, M. E. et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol. Cell. Biol. 25, 2441\u20132449 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"260_CR84","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.2605","volume":"219","author":"M Koch","year":"2009","unstructured":"Koch, M. et al. VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J. Pathol. 219, 356\u2013364 (2009).","journal-title":"J. Pathol."},{"key":"260_CR85","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1128\/MCB.02214-07","volume":"28","author":"P Haiko","year":"2008","unstructured":"Haiko, P. et al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol. Cell. Biol. 28, 4843\u20134850 (2008).","journal-title":"Mol. Cell. Biol."},{"key":"260_CR86","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41374-019-0259-0","volume":"99","author":"A Zarjou","year":"2019","unstructured":"Zarjou, A. et al. Dynamic signature of lymphangiogenesis during acute kidney injury and chronic kidney disease. Lab. Invest. 99, 1376\u20131388 (2019).","journal-title":"Lab. Invest."},{"key":"260_CR87","doi-asserted-by":"crossref","first-page":"F196","DOI":"10.1152\/ajprenal.00431.2005","volume":"291","author":"RR Foster","year":"2006","unstructured":"Foster, R. R. et al. VEGF-C promotes survival in podocytes. Am. J. Physiol. Renal Physiol. 291, F196\u2013F207 (2006).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"260_CR88","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2353\/ajpath.2008.070416","volume":"173","author":"RR Foster","year":"2008","unstructured":"Foster, R. R. et al. Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium. Am. J. Pathol. 173, 938\u2013948 (2008).","journal-title":"Am. J. Pathol."},{"key":"260_CR89","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-physiol-021115-105412","volume":"78","author":"CS Bartlett","year":"2016","unstructured":"Bartlett, C. S., Jeansson, M. & Quaggin, S. E. Vascular growth factors and glomerular disease. Annu. Rev. Physiol. 78, 437\u2013461 (2016).","journal-title":"Annu. Rev. Physiol."},{"key":"260_CR90","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3389\/fphys.2018.00973","volume":"9","author":"Z Armaly","year":"2018","unstructured":"Armaly, Z., Jadaon, J. E., Jabbour, A. & Abassi, Z. A. Preeclampsia: novel mechanisms and potential therapeutic approaches. Front. Physiol. 9, 973 (2018).","journal-title":"Front. Physiol."},{"key":"260_CR91","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1681\/ASN.2007020255","volume":"18","author":"IE Stillman","year":"2007","unstructured":"Stillman, I. E. & Karumanchi, S. A. The glomerular injury of preeclampsia. J. Am. Soc. Nephrol. 18, 2281\u20132284 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR92","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672\u2013683 (2004).","journal-title":"N. Engl. J. Med."},{"key":"260_CR93","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.117.10182","volume":"71","author":"S Agrawal","year":"2018","unstructured":"Agrawal, S., Cerdeira, A. S., Redman, C. & Vatish, M. Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study. Hypertension 71, 306\u2013316 (2018).","journal-title":"Hypertension"},{"key":"260_CR94","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler, H. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 374, 13\u201322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"260_CR95","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","volume":"124","author":"S Rana","year":"2019","unstructured":"Rana, S., Lemoine, E., Granger, J. & Karumanchi, S. A. Preeclampsia: pathophysiology, challenges, and perspectives. Circ. Res. 124, 1094\u20131112 (2019).","journal-title":"Circ. Res."},{"key":"260_CR96","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/HYPERTENSIONAHA.115.06783","volume":"67","author":"FT Spradley","year":"2016","unstructured":"Spradley, F. T. et al. Placental growth factor administration abolishes placental ischemia-induced hypertension. Hypertension 67, 740\u2013747 (2016).","journal-title":"Hypertension"},{"key":"260_CR97","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.116.07286","volume":"67","author":"A Makris","year":"2016","unstructured":"Makris, A. et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension 67, 1263\u20131272 (2016).","journal-title":"Hypertension"},{"key":"260_CR98","doi-asserted-by":"crossref","first-page":"H33","DOI":"10.1152\/ajpheart.00045.2018","volume":"315","author":"Z Ren","year":"2018","unstructured":"Ren, Z., Cui, N., Zhu, M. & Khalil, R. A. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy. Am. J. Physiol. Heart Circ. Physiol. 315, H33\u2013H47 (2018).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"260_CR99","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007216","volume":"6","author":"OC Logue","year":"2017","unstructured":"Logue, O. C., Mahdi, F., Chapman, H., George, E. M. & Bidwell, G. L., III. A maternally sequestered, biopolymer-stabilized vascular endothelial growth factor (VEGF) chimera for treatment of preeclampsia. J. Am. Heart Assoc. 6, e007216 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"260_CR100","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1172\/JCI99026","volume":"128","author":"JG Parchem","year":"2018","unstructured":"Parchem, J. G. et al. Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice. J. Clin. Invest. 128, 5008\u20135017 (2018).","journal-title":"J. Clin. Invest."},{"key":"260_CR101","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/j.1582-4934.2009.00820.x","volume":"14","author":"A Bergmann","year":"2010","unstructured":"Bergmann, A. et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J. Cell. Mol. Med. 14, 1857\u20131867 (2010).","journal-title":"J. Cell. Mol. Med."},{"key":"260_CR102","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2012.08.037","volume":"151","author":"J Jin","year":"2012","unstructured":"Jin, J. et al. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 151, 384\u2013399 (2012).","journal-title":"Cell"},{"key":"260_CR103","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/nbt.4297","volume":"36","author":"AA Turanov","year":"2018","unstructured":"Turanov, A. A. et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 36, 1164\u20131173 (2018).","journal-title":"Nat. Biotechnol."},{"key":"260_CR104","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMcibr1817501","volume":"380","author":"SA Robertson","year":"2019","unstructured":"Robertson, S. A. Preventing preeclampsia by silencing soluble Flt-1? N. Engl. J. Med. 380, 1080\u20131082 (2019).","journal-title":"N. Engl. J. Med."},{"key":"260_CR105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/HYPERTENSIONAHA.118.12380","volume":"74","author":"L Trapiella-Alfonso","year":"2019","unstructured":"Trapiella-Alfonso, L. et al. VEGF (vascular endothelial growth factor) functionalized magnetic beads in a microfluidic device to improve the angiogenic balance in preeclampsia. Hypertension 74, 145\u2013153 (2019).","journal-title":"Hypertension"},{"key":"260_CR106","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861\u2013869 (2001).","journal-title":"N. Engl. J. Med."},{"key":"260_CR107","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306 (2019).","journal-title":"N. Engl. J. Med."},{"key":"260_CR108","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TW Tervaert","year":"2010","unstructured":"Tervaert, T. W. et al. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 21, 556\u2013563 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR109","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","volume":"124","author":"K Reidy","year":"2014","unstructured":"Reidy, K., Kang, H. M., Hostetter, T. & Susztak, K. Molecular mechanisms of diabetic kidney disease. J. Clin. Invest. 124, 2333\u20132340 (2014).","journal-title":"J. Clin. Invest."},{"key":"260_CR110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrneph.2010.152","volume":"7","author":"T Nakagawa","year":"2011","unstructured":"Nakagawa, T. et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat. Rev. Nephrol. 7, 36\u201344 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"260_CR111","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1681\/ASN.2006050459","volume":"18","author":"T Nakagawa","year":"2007","unstructured":"Nakagawa, T. et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol. 18, 539\u2013550 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR112","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/labinvest.2008.23","volume":"88","author":"S Mohan","year":"2008","unstructured":"Mohan, S. et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab. Invest. 88, 515\u2013528 (2008).","journal-title":"Lab. Invest."},{"key":"260_CR113","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.ajkd.2004.09.020","volume":"45","author":"Y Kanesaki","year":"2005","unstructured":"Kanesaki, Y. et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am. J. Kidney Dis. 45, 288\u2013294 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"260_CR114","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00125-010-2034-z","volume":"54","author":"D Veron","year":"2011","unstructured":"Veron, D. et al. Podocyte vascular endothelial growth factor (VEGF(1)(6)(4)) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 54, 1227\u20131241 (2011).","journal-title":"Diabetologia"},{"key":"260_CR115","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1681\/ASN.2013070752","volume":"25","author":"D Veron","year":"2014","unstructured":"Veron, D. et al. Podocyte-specific VEGF-a gain of function induces nodular glomerulosclerosis in eNOS null mice. J. Am. Soc. Nephrol. 25, 1814\u20131824 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR116","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.ki.5002101","volume":"71","author":"HJ Baelde","year":"2007","unstructured":"Baelde, H. J. et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 71, 637\u2013645 (2007).","journal-title":"Kidney Int."},{"key":"260_CR117","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.2337\/DB11-1655","volume":"61","author":"GA Sivaskandarajah","year":"2012","unstructured":"Sivaskandarajah, G. A. et al. Vegfa protects the glomerular microvasculature in diabetes. Diabetes 61, 2958\u20132966 (2012).","journal-title":"Diabetes"},{"key":"260_CR118","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.2012121218","volume":"25","author":"C Dessapt-Baradez","year":"2014","unstructured":"Dessapt-Baradez, C. et al. Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J. Am. Soc. Nephrol. 25, 33\u201342 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR119","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1084\/jem.20180009","volume":"216","author":"IA Carota","year":"2019","unstructured":"Carota, I. A. et al. Targeting VE-PTP phosphatase protects the kidney from diabetic injury. J. Exp. Med. 216, 936\u2013949 (2019).","journal-title":"J. Exp. Med."},{"key":"260_CR120","volume":"9","author":"N Hinamoto","year":"2014","unstructured":"Hinamoto, N. et al. Exacerbation of diabetic renal alterations in mice lacking vasohibin-1. PLoS One 9, e107934 (2014).","journal-title":"PLoS One"},{"key":"260_CR121","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/db08-1790","volume":"58","author":"T Nasu","year":"2009","unstructured":"Nasu, T. et al. Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 58, 2365\u20132375 (2009).","journal-title":"Diabetes"},{"key":"260_CR122","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1016\/j.ajpath.2018.08.005","volume":"188","author":"P Bus","year":"2018","unstructured":"Bus, P. et al. Endoglin mediates vascular endothelial growth factor-A-induced endothelial cell activation by regulating Akt signaling. Am. J. Pathol. 188, 2924\u20132935 (2018).","journal-title":"Am. J. Pathol."},{"key":"260_CR123","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db18-0045","volume":"68","author":"KL Onions","year":"2019","unstructured":"Onions, K. L. et al. VEGFC reduces glomerular albumin permeability and protects against alterations in VEGF receptor expression in diabetic nephropathy. Diabetes 68, 172\u2013187 (2019).","journal-title":"Diabetes"},{"key":"260_CR124","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(16)00272-5","volume":"387","author":"J Floege","year":"2016","unstructured":"Floege, J. & Amann, K. Primary glomerulonephritides. Lancet 387, 2036\u20132048 (2016).","journal-title":"Lancet"},{"key":"260_CR125","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/ki.2009.75","volume":"75","author":"Y Avihingsanon","year":"2009","unstructured":"Avihingsanon, Y. et al. Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis. Kidney Int. 75, 1340\u20131348 (2009).","journal-title":"Kidney Int."},{"key":"260_CR126","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/labinvest.2008.60","volume":"88","author":"W Sato","year":"2008","unstructured":"Sato, W. et al. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab. Invest. 88, 949\u2013961 (2008).","journal-title":"Lab. Invest."},{"key":"260_CR127","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1172\/JCI86418","volume":"127","author":"LS Keir","year":"2017","unstructured":"Keir, L. S. et al. VEGF regulates local inhibitory complement proteins in the eye and kidney. J. Clin. Invest. 127, 199\u2013214 (2017).","journal-title":"J. Clin. Invest."},{"key":"260_CR128","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.kint.2017.02.036","volume":"92","author":"R Schmitt","year":"2017","unstructured":"Schmitt, R. & Melk, A. Molecular mechanisms of renal aging. Kidney Int. 92, 569\u2013579 (2017).","journal-title":"Kidney Int."},{"key":"260_CR129","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ki.2012.65","volume":"82","author":"RJ Glassock","year":"2012","unstructured":"Glassock, R. J. & Rule, A. D. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int. 82, 270\u2013277 (2012).","journal-title":"Kidney Int."},{"key":"260_CR130","doi-asserted-by":"crossref","first-page":"F1648","DOI":"10.1152\/ajprenal.00099.2008","volume":"295","author":"EC Leonard","year":"2008","unstructured":"Leonard, E. C., Friedrich, J. L. & Basile, D. P. VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am. J. Physiol. Renal Physiol. 295, F1648\u2013F1657 (2008).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"260_CR131","doi-asserted-by":"crossref","first-page":"F721","DOI":"10.1152\/ajprenal.00546.2010","volume":"300","author":"DP Basile","year":"2011","unstructured":"Basile, D. P. et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am. J. Physiol. Renal Physiol. 300, F721\u2013F733 (2011).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"260_CR132","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1681\/ASN.2006010075","volume":"18","author":"E Liu","year":"2007","unstructured":"Liu, E. et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J. Am. Soc. Nephrol. 18, 2094\u20132104 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR133","volume":"11","author":"S Singh","year":"2016","unstructured":"Singh, S. et al. Tubular overexpression of angiopoietin-1 attenuates renal fibrosis. PLoS One 11, e0158908 (2016).","journal-title":"PLoS One"},{"key":"260_CR134","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/acel.12497","volume":"15","author":"E Takeda","year":"2016","unstructured":"Takeda, E., Suzuki, Y. & Sato, Y. Age-associated downregulation of vasohibin-1 in vascular endothelial cells. Aging Cell 15, 885\u2013892 (2016).","journal-title":"Aging Cell"},{"key":"260_CR135","doi-asserted-by":"crossref","unstructured":"Watatani, H. et al. Vasohibin-1 deficiency enhances renal fibrosis and inflammation after unilateral ureteral obstruction. Physiol. Rep. 2 (2014).","DOI":"10.14814\/phy2.12054"},{"key":"260_CR136","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/ki.2012.312","volume":"83","author":"AS Lee","year":"2013","unstructured":"Lee, A. S. et al. Vascular endothelial growth factor-C and -D are involved in lymphangiogenesis in mouse unilateral ureteral obstruction. Kidney Int. 83, 50\u201362 (2013).","journal-title":"Kidney Int."},{"key":"260_CR137","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.kint.2017.03.029","volume":"92","author":"H Kinashi","year":"2017","unstructured":"Kinashi, H. et al. Connective tissue growth factor regulates fibrosis-associated renal lymphangiogenesis. Kidney Int. 92, 850\u2013863 (2017).","journal-title":"Kidney Int."},{"key":"260_CR138","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fimmu.2019.00308","volume":"10","author":"S Schwager","year":"2019","unstructured":"Schwager, S. & Detmar, M. Inflammation and lymphatic function. Front. Immunol. 10, 308 (2019).","journal-title":"Front. Immunol."},{"key":"260_CR139","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/labinvest.2017.77","volume":"97","author":"S Hasegawa","year":"2017","unstructured":"Hasegawa, S. et al. Vascular endothelial growth factor-C ameliorates renal interstitial fibrosis through lymphangiogenesis in mouse unilateral ureteral obstruction. Lab. Invest. 97, 1439\u20131452 (2017).","journal-title":"Lab. Invest."},{"key":"260_CR140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000369076","volume":"40","author":"T Ruge","year":"2014","unstructured":"Ruge, T. et al. Endostatin level is associated with kidney injury in the elderly: findings from two community-based cohorts. Am. J. Nephrol. 40, 417\u2013424 (2014).","journal-title":"Am. J. Nephrol."},{"key":"260_CR141","doi-asserted-by":"crossref","first-page":"H1692","DOI":"10.1152\/ajpheart.00064.2014","volume":"306","author":"CH Lin","year":"2014","unstructured":"Lin, C. H. et al. Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy? Am. J. Physiol. Heart Circ. Physiol. 306, H1692\u2013H1699 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"260_CR142","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1042\/BJ20091594","volume":"427","author":"C Faye","year":"2010","unstructured":"Faye, C. et al. Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells. Biochem. J. 427, 467\u2013475 (2010).","journal-title":"Biochem. J."},{"key":"260_CR143","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.kint.2016.01.030","volume":"89","author":"CH Lin","year":"2016","unstructured":"Lin, C. H. et al. Endostatin and transglutaminase 2 are involved in fibrosis of the aging kidney. Kidney Int. 89, 1281\u20131292 (2016).","journal-title":"Kidney Int."},{"key":"260_CR144","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1681\/ASN.2016040425","volume":"27","author":"WN Leonhard","year":"2016","unstructured":"Leonhard, W. N., Happe, H. & Peters, D. J. Variable cyst development in autosomal dominant polycystic kidney disease: the biologic context. J. Am. Soc. Nephrol. 27, 3530\u20133538 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR145","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.ki.5001725","volume":"70","author":"W Wei","year":"2006","unstructured":"Wei, W., Popov, V., Walocha, J. A., Wen, J. & Bello-Reuss, E. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int. 70, 1261\u20131268 (2006).","journal-title":"Kidney Int."},{"key":"260_CR146","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1681\/ASN.2015010067","volume":"27","author":"T Suwabe","year":"2016","unstructured":"Suwabe, T. et al. Suitability of patients with autosomal dominant polycystic kidney disease for renal transcatheter arterial embolization. J. Am. Soc. Nephrol. 27, 2177\u20132187 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR147","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/hmg\/ddp165","volume":"18","author":"X Song","year":"2009","unstructured":"Song, X. et al. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum. Mol. Genet. 18, 2328\u20132343 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"260_CR148","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5002550","volume":"72","author":"Y Tao","year":"2007","unstructured":"Tao, Y. et al. VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int. 72, 1358\u20131366 (2007).","journal-title":"Kidney Int."},{"key":"260_CR149","doi-asserted-by":"crossref","first-page":"F773","DOI":"10.1152\/ajprenal.00058.2011","volume":"301","author":"S Raina","year":"2011","unstructured":"Raina, S. et al. Anti-VEGF antibody treatment accelerates polycystic kidney disease. Am. J. Physiol. Renal Physiol. 301, F773\u2013F783 (2011).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"260_CR150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1681\/ASN.2014090856","volume":"27","author":"JL Huang","year":"2016","unstructured":"Huang, J. L. et al. Vascular endothelial growth factor C for polycystic kidney diseases. J. Am. Soc. Nephrol. 27, 69\u201377 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"260_CR151","doi-asserted-by":"crossref","first-page":"R783","DOI":"10.1152\/ajpregu.00657.2010","volume":"300","author":"AR Chade","year":"2011","unstructured":"Chade, A. R. Renovascular disease, microcirculation, and the progression of renal injury: role of angiogenesis. Am. J. Physiol. Regulatory, Integr. Comp. Physiol. 300, R783\u2013R790 (2011).","journal-title":"Am. J. Physiol. Regulatory, Integr. Comp. Physiol."},{"key":"260_CR152","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1310753","volume":"370","author":"CJ Cooper","year":"2014","unstructured":"Cooper, C. J. et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N. Engl. J. Med. 370, 13\u201322 (2014).","journal-title":"N. Engl. J. Med."},{"key":"260_CR153","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.kint.2016.12.023","volume":"92","author":"A Eirin","year":"2017","unstructured":"Eirin, A. et al. Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation. Kidney Int. 92, 114\u2013124 (2017).","journal-title":"Kidney Int."},{"key":"260_CR154","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/0963689718780942","volume":"27","author":"A Eirin","year":"2018","unstructured":"Eirin, A. et al. Mesenchymal stem cell-derived extracellular vesicles improve the renal microvasculature in metabolic renovascular disease in swine. Cell Transplant. 27, 1080\u20131095 (2018).","journal-title":"Cell Transplant."},{"key":"260_CR155","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.kint.2017.09.029","volume":"93","author":"AR Chade","year":"2018","unstructured":"Chade, A. R. et al. Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease. Kidney Int. 93, 842\u2013854 (2018).","journal-title":"Kidney Int."},{"key":"260_CR156","doi-asserted-by":"crossref","first-page":"F54","DOI":"10.1152\/ajprenal.00143.2016","volume":"312","author":"GL Bidwell 3rd","year":"2017","unstructured":"Bidwell, G. L., 3rd et al. A kidney-selective biopolymer for targeted drug delivery. Am. J. Physiol. Renal Physiol. 312, F54\u2013F64 (2017).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"260_CR157","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.119.13469","volume":"74","author":"JE Engel","year":"2019","unstructured":"Engel, J. E., Williams, E., Williams, M. L., Bidwell, G. L., 3rd & Chade, A. R. Targeted VEGF (vascular endothelial growth factor) therapy induces long-term renal recovery in chronic kidney disease via macrophage polarization. Hypertension 74, 1113\u20131123 (2019).","journal-title":"Hypertension"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41581-020-0260-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-020-0260-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-020-0260-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:09:24Z","timestamp":1684620564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-020-0260-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":157,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["260"],"URL":"https:\/\/doi.org\/10.1038\/s41581-020-0260-2","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"11 February 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}